New Sanofi study is yet another win for blockbuster drug
Both primary and secondary endpoints were met in a new phase III trial of Sanofi's bestseller drug Dupixent, this time as a treatment for the rare skin disease prurigo nodularis.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL PEDERSEN
Sanofi is working to expand the indications for its blockbuster drug Dupixent. The firm's latest attempt looks to be a success, as a phase III study generated positive results within skin disease prurigo nodularis.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Sanofi's eczema drug is four-time blockbuster
For subscribers
CHMP recommends six new drugs
For subscribers
